BILLERICA, Mass.– Quanterix Corporation (NASDAQ: QTRX), a leader in ultrasensitive biomarker detection, has introduced a new dried blood spot (DBS) extraction kit as part of its Simoa® assay portfolio. The announcement was made at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) in Vienna, Austria, where Quanterix’s innovative technology was showcased in more than 80 research presentations.
The new DBS extraction kit represents a breakthrough in biomarker testing by allowing researchers to analyze low-concentration biomarkers from dried blood spots. This approach offers a cost-effective and minimally invasive alternative to traditional venous blood draws, which can be complex and limit accessibility, particularly in remote or undeserved areas.
Developed in collaboration with the University of Gothenburg’s DROP-AD Project, the kit includes specialized buffers and a sample preparation protocol that facilitates the accurate and sensitive measurement of neurodegenerative disease biomarkers. Validation studies demonstrated a strong correlation between DBS samples processed with the Simoa ALZpath p-Tau 217 assay and venous blood samples, with correlation coefficients ranging from 0.75 to 0.86.
“Our new dried blood spot extraction kit represents a major step forward in making biomarker testing more accessible,” said Masoud Toloue, PhD, Chief Executive Officer of Quanterix. “By simplifying sample collection, DBS has the potential to expand participation in Alzheimer’s research and clinical trials—especially among under-represented populations. This advancement will deepen our ability to understand the disease and its progression across diverse communities.”
Beyond the launch of the DBS extraction kit, Quanterix’s Simoa technology was prominently featured at AD/PD, with over 80 posters and presentations demonstrating its growing impact on neurodegenerative disease research. The company’s innovations continue to play a crucial role in advancing diagnostics and broadening access to critical testing solutions worldwide.
